Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologists who Treat Myelodysplastic Syndromes

Articles with lock require a subscription to GLG News | Request a free trial
September 2, 2008
GIST: So what else is new.....
Analysis of: Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Novartis is looking for approval for therapy in C-KIT + Gastrointestinal stromal tumors
August 29, 2008
Bcl-2 apoptosis inhibition: The next "best" thing?
Analysis of: Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents | jco.ascopubs.org
Author: GLG Expert Contributor
Bcl-2 inhibition by small molecules stands to be the next avenue for antineoplastic therapy- Looks like the real deal!
August 29, 2008
So Much for GVAX.... for now?
Analysis of: Cell Genesys Ends Clinical Trials For Prostate Cancer Treatment | online.wsj.com
Author: GLG Expert Contributor
No reason for the increased mortality vs Chemo alone was identified. Cell Genesys is looking into where to go now.
August 29, 2008
Velcade in myeloma 1st line. Am I s?urprised
Analysis of: Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma | content.nejm.org
Author: GLG Expert Contributor
Velcade + classic Melphalan/ Prednisone  (MP) is better than MP alone. No surprise
August 25, 2008
Amgen's long awaited product to treat chronic ITP will be well receive.
Analysis of: Amgen Blood-Disorder Drug Gains Clearance | online.wsj.com
Author: GLG Expert Contributor
Chronic ITP is not all that uncommon and becomes a quality of life issue with chronic steroid use as well as agents that are normaly used in neoplasia and even derivatives of male hormones.
August 21, 2008
Artificial red blood cells (RBC'S): preliminary but very promising.
Analysis of: Scientists Find Way to Create Red Blood Cells | online.wsj.com
Author: GLG Expert Contributor
Advanced Cell Technology in Worcester, Mass., the University of Illinois at Chicago and the Mayo Clinic in Rochester, Minn. scientists say they've found an efficient way to make red blood cells from human embryonic stem cells. Impreesive!
August 21, 2008
Cervical Cancer Vaccines: Hope or Hype?
Analysis of: Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise | www.nytimes.com
Author: GLG Expert Contributor
Cervical cancer vaccines manufactured by Merck and Glaxo have been hyped, pushed and if the companies have their way, mandated by various states and organizations. (Who is benefiting? Patients or the politicians?) There are many unanswered questions but marketing and mandates press on!
August 20, 2008
Sunitinib vs Interferon: No contest at the onset
Analysis of: Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma | jco.ascopubs.org
Author: GLG Expert Contributor
When using a model (of whose desin?) Pfizer's Sunitinib (Sutent) was found to be cost effective by Pfizer people? Surprise!!!
August 19, 2008
Cole & Pfizer: Happy together in NSCLCA (non small cell lung cancer)
Analysis of: Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
"The investigator-assessed objective response rate (complete and partial response), including both confirmed and unconfirmed responses, was 38% in the PF-3512676 plus chemotherapy arm and 19% in the chemotherapy-alone arm (P = .043)." In other words. IT MAY WORK!
August 15, 2008
BiovaxID: Does It Work?
Analysis of: Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID(R) Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial | biz.yahoo.com
Author: Donald Tsai, Assistant Professor of Medicine, University of Pennsylvania Cancer Center
1) BiovaxID shows a 100% improvement in DFS at 3 years (p=0.24) 2) BiovaxID shows an improvement in median overall DFS with a significant P value (p=0.047) 2) This is the first lymphoma vaccine with a suggestion of activity. 3) BiovaxID shows evidence of activity despite the failure of 2 other...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next41 to 50 of 539

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747